SCHEMBL14830797

SCHEMBL14830797

C=CCN(C(=O)OC(C)(C)C)c1ccc(Cl)cc1Br

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.38
KDM4E B2RXH2 3/20 0.36
GAA P10253 2/20 0.35
TSHR P16473 1/20 0.35
NPSR1 Q6W5P4 2/20 0.34
TDP1 Q9NUW8 1/20 0.33
POLB P06746 1/20 0.33
HPGD P15428 1/20 0.33
MT-CO2 P00403 1/20 0.33
SMN1; SMN2 Q16637 1/20 0.33
MEN1 O00255 2/20 0.32
KMT2A Q03164 2/20 0.32
NPC1 O15118 1/20 0.32
GABRP O00591 1/20 0.32
GABRD O14764 1/20 0.32
GABRA1 P14867 1/20 0.32
GABRB1 P18505 1/20 0.32
GABRG2 P18507 1/20 0.32
GABRB3 P28472 1/20 0.32
GABRA5 P31644 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14830864 0.89 MT-CO2 (0.38) ALDH1A1KDM4EGAAMT-CO2SMN1; SMN2
SCHEMBL14830160 0.80 KDM4E (0.41) ALDH1A1KDM4EGAATSHRTDP1
SCHEMBL5879111 0.77 S1PR1 (0.35) ALDH1A1TSHRMT-CO2L3MBTL1
SCHEMBL3229659 0.76 RAB9A (0.32) ALDH1A1TSHRL3MBTL1
SCHEMBL31679532 0.74 SMN1; SMN2 (0.43) ALDH1A1KDM4EGAATSHRNPSR1
SCHEMBL3846164 0.73 L3MBTL1 (0.31) TSHRL3MBTL1
SCHEMBL3219458 0.73 GPBAR1 (0.34) ALDH1A1TSHRL3MBTL1
SCHEMBL3221801 0.73 POLB (0.40) ALDH1A1KDM4EGAATSHRTDP1
SCHEMBL15466723 0.73 SSTR4 (0.35) ALDH1A1KDM4EGAATSHRNPSR1
SCHEMBL22798736 0.73 NCEH1 (0.34) KDM4ESMN1; SMN2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2760845-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER Amgen Inc. (US) 2014-08-06 EP disclosed
WO-2013049250-A1 HETEROCYCLIC COMPOUNDS AS MDM2 INHIBITORS FOR THE TREATMENT OF CANCER AMGEN INC. (US) 2013-04-04 WO disclosed